The colicin V production and immunity genes were isolated from plasmid pColV-K30. A HindIH-to-SalI fragment of 9.4 kilobases was cloned into the compatible vectors pBR322 and pACYC184. Mutants defective in colicin production were generated by TnS insertions and by constructing deletions in vitro. Physical analysis of these mutations identified a 4.4-kilobase region of this DNA which contains all the plasmid genes (cva) needed for the production of colicin V. The colicin V immunity determinant (cvI) iS in a 700-base-pair fragment located within one end of this region. Complementation tests Identified three genes, called cvaA, cvaB, and cvaC, required for colicin production. Analysis of the proteins labeled in minicells harboring various TnS insertions allowed us to identify protein products for the cvaA and cvaC genes. Mutations in cvaA and cvaB eliminated colicin activity in culture supernatants, but not within the cells. Mutations in cvaC, however, eliminated all detectable activity. From these results we conclude that the cvaC gene codes for the structural gene for colicin V, while cvaA and cvaB are apparently needed for the normal export of the colicin.
The colicin V production and immunity genes were isolated from plasmid pColV-K30. A HindIH-to-SalI fragment of 9.4 kilobases was cloned into the compatible vectors pBR322 and pACYC184. Mutants defective in colicin production were generated by TnS insertions and by constructing deletions in vitro. Physical analysis of these mutations identified a 4.4-kilobase region of this DNA which contains all the plasmid genes (cva) needed for the production of colicin V. The colicin V immunity determinant (cvI) iS in a 700-base-pair fragment located within one end of this region. Complementation tests Identified three genes, called cvaA, cvaB, and cvaC, required for colicin production. Analysis of the proteins labeled in minicells harboring various TnS insertions allowed us to identify protein products for the cvaA and cvaC genes. Mutations in cvaA and cvaB eliminated colicin activity in culture supernatants, but not within the cells. Mutations in cvaC, however, eliminated all detectable activity. From these results we conclude that the cvaC gene codes for the structural gene for colicin V, while cvaA and cvaB are apparently needed for the normal export of the colicin.
Colicin V is a small, proteinaceous toxin whose activity along with an immunity determinant is encoded on large, low-copy-number plasmids (14) . ColV plasmids have been found naturally occuring in many strains of Escherichia coli and other members of the family Enterobacteriaceae. These bacteria also define the activity range for colicin V. Its target for growth inhibition is thought to be the cytoplasmic membrane, where it prevents the formation of membrane potential (32) . ColV plasmids are often associated with E. coli invasiveness and pathogenicity (29, 30) . These plasmids also often carry genes which may enhance the ability of cells to proliferate within the host. Examples of these are the aerobactin iron uptake genes (31) and a gene for increased serum resistance (5) . In addition, an enhanced adherence to intestinal epithelial cells has been noted in strains harboring ColV plasmids (11) . Colicin V production does not appear to be a virulence determinant, but it has been hypothesized that it may help to selectively maintain these genes (26, 31) .
The colicin V toxin is distinguished from other colicins by the small size of the active protein (13) and by its constitutive, rather than SOS-inducible, synthesis (15) . There is also no evidence that, like many colicins, colicin V accumulates in the cell before its release or has a lysis gene product responsible for its release (25) .
Frick et al. (13) cloned a 900-base-pair (bp) region of the pColV-B188 plasmid which included the colicin V immunity gene (cvi) and an apparent colicin V structural gene (cva). However, cells harboring this cloned fragment did not produce growth inhibition zones on a lawn of sensitive cells, and culture supematants did not contain assayable amounts of colicin. The killing activity coded by this 900-bp fragment could only be assayed after lysing the cells and appeared to be fourfold-less potent than that coded by a much larger fragment (13) . In this paper we show that a 4.4-kilobase (kb) region of DNA containing cvi and at least three other genes is necessary for the normal production and export of killing activity.
MATERIALS AND METHOIDS
Bacterial strains and plasmids. The bacterial strains and plasmids used in this study are listed in Table 1 .
Media and culture conditions. Media were prepared as described by Miller (24) . Antibiotics were used at the following concehtrations (micrograms per milliliter): ampicillin, 150; chloramphenicol, 20; and kanamycin, 50.
DNA manipulations and colicin V assays. Plasmid DNA preparation, digestions, ligations, transformations, and electrophoresis were performed as described previously (6, 12, 21) . Colicin V activity and immunity were determined as described previously (13) . Activity was quantitated by the critical dilution method (22) .
TnS mutagenesis. Transposition of TnS into pHK11 and pHK22 was accomplished by introducing these plasmids into strain DB1358 (28) . To ensure independent insertions into many different sites, 20 colonies of DB1358 harboring each plasmid were grown independently, and plasmid DNA was prepared. This DNA was then used to transformn MC4100, selecting for resistance to kanamycin and ampicillin for the pHK11 derivatives and to kanamyciri and chloramphenicol for the pHK22 derivatives. About 10% of these colonies no longer produced colicin V. To map the TnS insertion sites, BglII, HindIII and BamHI digests were done, thereby using the precisely known restriction sites within the IS50 of TnS (16) and the unique sites in pHK11 or pHK22.
Complementation testing. Each cva : :Tn5 mutant from pHKll was used to cotransform ZK4 in combination with each cva::TnS mutant from pHK22. Transformants were selected as being simultaneously resistant to kanamycin, amnpicillin, and chloramphenicol. From each transformation, six colonies were tested for colicin V production. The ability to form a zone of growth inhibition was interpreted as positive complementation. No cases of partial complementation were observed. In every case, all six colonies tested gave the same results. In addition, we confirmed the presence of two separate plasmids on several of the double transformants.
Preparation of minicells, protein labeling, and protein analysis. Strain P678-54T-was transformed with pHK22 and 
RESULTS
Cloning of colicin V genes. HindIII fragments from a complete digest of pColV-K30 DNA were ligated with HindIII-cut pBR322. This ligation mixture was used to transform strain MC4100. Ampicillin-resistant transformants were selected and screened for colicin V production on the basis of zones of growth inhibition surrounding the colonies. Apparent colicin-producing clones were further purified and tested for colicin V activity and immunity. Plasmid DNA was then subjected to restriction analysis. For each of the clones tested, the pBR322 plasmid derivative contained a 20-kb HindIII fragment insertion. The two possible orienta- tions of the fragment inserted were designated pHK3 and pHK4.
After a restriction map of pHK4 was generated ( Fig. 1 ), deletions were made in the plasmid by cutting with endonucleases and religating. One deletion, a SalI digestion followed by religation, still maintained both colicin V production and immunity. This plasmid was called pHKll (Fig.  1) . The growth inhibition zones generated by pHKll and other high-copy-number clones were larger than those observed with the wild-type pColV-K30.
Subcloning of pHK11. Three fragments of pHKll were subcloned separately into pMK16, and the resultant constructs were assayed for colicinogenic and immunity properties (Fig. 2) . The plasmids containing 2.2-or 1.5-kb BamHI-EcoRI fragments did not confer colicin production or immunity properties on the cells. Cells which contained the SalI-BamHI (5.2-kb) fragment did not produce colicin V but were immune to colicin V (Cva-Cvi+). Similarly, the KpnI-BglII (4.2-kb) fragment cloned into pUC19 resulted in cells (strain JM83) with a Cva-Cvi+ phenotype. However, cells (strain 71-18) with M13tgl31 containing the HindIllBglIl (7.2-kb) fragment were Cva+ Cvi+.
TnS mutagenesis and complementation analysis. To better localize the colicin production region and to perform complementation experiments, we constructed pHK22, a derivative of pACYC184 which contains the same Sail-HindIll (9.4-kb) fragment as pHKll and is compatible with pHK11. Inhibition zones from strains harboring pHK22 were approximately the same size as those from strains containing pHK11. Both pHKll and pHK22 were mutagenized with TnS as described in Materials and Methods. Only two phenotypes with respect to colicin V production were obtained: colonies which still produced normal-sized growth inhibition zones and colonies which completely failed to produce growth inhibition zones.
The insertion sites for 11 cva::TnS mutants in pHKll and for 13 such mutants in pHK22 were determined by restriction site analysis (Fig. 2) pHK22-8, -2, and -13 did not complement each other but were complemented by all other TnS mutations. Likewise, pHK1-11, -4, -3, -6, and -2 and pHK22-1, -5, -9, -10, -4, -14, -7, and -11 formed another complementation group, and a third group was formed by pHKll-9 and -1 and pHK22-6. We have designated these contiguous genes cvaA, cvaB, and cvaC (Fig. 2) . The left-hand boundary of cvaA must lie between pHK22-3, a Cva+ TnS insertion, and the Kpnl site, while the right-hand boundary lies between pHK11-8 and pHK11-11. The boundaries for cvaB are between pHK11-8 and pHK11-11 on the left and between pHK11-2 and pHK11-9 on the right. The cvaC gene boundaries must lie between pHK11-2 and pHK11-9 on the left and between pHK22-6 and the BglII site on the right (Fig. 2) Mapping of the immunity region. All cva:: Tn insertion mutants were tested for immunity to colicin V and were Cvi+. A BamHI-BglII deletion in pHK11 (Fig. 2) gave a Cviphenotype. We then used the HindIll site from within the IS50 of pHK11-1 to clone a 1.9-kb HindIII-BglII fragment containing 1, 195 bp from TnS and 700 bp of ColV DNA into another vector, pUC19. When JM83 cells were transformed with this pUC19 derivative, the cells were Cvi+. Therefore, the cvi gene(s) lies within the 700-bp region between the BglII site and the rightmost TnS insertion in pHK11, pHK11-1 (Fig. 2) .
Identification of cva gene products. The protein products of pHK11, pHK22, and the TnS insertion derivatives were analyzed in minicells. Two or three mutants in each complementation group were analyzed in this way with identical results. The results shown in Fig. 3 and 4 are from pHK22, pHKI22-6, pHK22-9, and pHK22-8. The 12.5% SDSpolyacrylamide gel shows two proteins, with masses of 27 and 43 kilodaltons (kDa), which are affected by a disruption of the cvaA gene (Fig. 3) . In Fig. 4 , the 21% gel shows a protein of approximately 6 kDa as a gene product for cvaC. Lane 5 of Fig. 4 , which contains plasmid proteins from cvaC cvi mutant cells, lacks both the 6,000-molecular-weight (MW) protein and an approximately 7,000-MW protein. The latter protein is seen as a very faint band produced by the pUC19 plasmid with the 1.9-kb cvi-containing insert described above. Therefore, this protein is likely to be responsible for colicin V immunity.
DISCUSSION
We have identified a 4.2-kb region of plasmid pColV-K30 which is responsible for the production of colicin V and immunity to it. TnS mutagenesis and complementation analysis defined three complementation groups involved in normal colicin V production. The three genes defined by the complementation groups, cvaA, cvaB, and cvaC, are encoded contiguously (Fig. 2) and could be transcribed as part of an operon. The lack of strong polarity by the TnS insertions suggests that each gene has its own transcriptional promoter. However, instances in which transposon insertions do not show polarity have been described (27) . These instances could be due to outward promoters from the ends of transposons (4, 10) or to transcription antitermination (20) . The immunity gene, cvi, is within a 700-bp region adjacent to, or possibly overlapping, the cvaC gene (Fig. 2) .
Mutations in cvaA abolished the production in minicells of two proteins of approximately 27 In an earlier study of the genes necessary for colicin V activity and immunity, Frick et al. (13) obtained a plasmid essentially identical to pHKll from pColV-B188. In that study, the structural gene for colicin V and the immunity gene were mapped to the EcoRI-BglII fragment (Fig. 2) . The fragment carrying these genes was then reduced to a 900-bp HaeIII-RsaI fragment. These 900 bp would cover the region of cvaC and cvi defined in the present study. While the 900-bp fragment coded for colicin V activity, this activity could only be detected in extracts of lysed cells. In our study, lysed-cell extracts from cvaA and cvaB mutants showed activity, while those from cvaC mutants did not. Supernatants from all three mutant cultures also showed no detectable activity. Since strains harboring plasmids with the wild-type HindIII-SalI fragment yielded active colicin V both within the cells and in the supernatant, these results suggest that cvaC is the structural gene for colicin V and that the products of the other two genes, cvaA and cvaB, are necessary for the proper export or release of the colicin. Comparison of the cloned region of pColV-B188 (13) with that of pColV-K30 shows extensive homology. There are some minor differences in the number of and distance between several restriction sites, which could reflect polymorphisms between the two parent ColV plasmids.
Most colicin plasmids contain a cluster of three genes involved in the production and release of the colicin: the colicin structural gene, the colicin immunity gene, and a lysis gene (25) . The results described here indicate that the genes involved in colicin V production do not follow this pattern. Our work on the genetic arrangement of colicin V production and immunity genes, along with the evidence that colicin V is not induced by DNA damage (15) , supports the suggestion that colicin V can be considered a microcin (32) . Microcins constitute a family of low-molecular-weight antibiotic substances produced by many Enterobacteriaceae (2, 3) . Unlike the colicins, none of the microcins is inducible by DNAdamaging agents.
Further research into the production and function of colicin V and microcins in general should prove to be useful in the understanding of peptide and small-protein transport in E. coli. It is likely that colicin V must cross the double membrane and cell wall of the producer cell and must then span at least part of the envelope barrier of the susceptible cell. The export and uptake of this protein could be different from that of the larger colicins, which are thought to first accumulate in the producing cell and then to rely on a lysis gene product for export (25) .
